Sanofi (SNY) News
Follow Sanofi (SNY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 32 public stories across 20 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Nurix Shares Fall 36.9% After Sanofi Discontinues STAT6 Drug Program
EQUITY | Nov 04, 2026, 07:50 PM UTC
M
U.S. ETFs and Equity Futures Rise Before Wednesday's Open
Exchange-traded funds and equity futures rose before the U.S. market open.
EQUITY | Nov 04, 2026, 02:22 PM UTC
M
Sanofi Raises 2026 Outlook as Q3 Earnings and Revenue Rise
Sanofi reported higher fiscal Q3 adjusted earnings and revenue and raised its 2026 outlook.
EQUITY | Oct 30, 2026, 07:33 AM UTC
M
Novavax Earns $125 Million Milestone Payment From Sanofi Vaccine Trial
Novavax earned a $125 million milestone payment from Sanofi's Phase 3 vaccine trial in Europe.
EQUITY | Oct 29, 2026, 02:38 PM UTC
M
Sanofi Expected to Post Earnings of $1.51 a Share
An earnings preview expects Sanofi to report earnings of $1.51 per share.
EQUITY | Oct 28, 2026, 08:04 AM UTC
H
Full Transcript: Sanofi Q2 2026 Earnings Call
Sanofi (NASDAQ: SNY ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcri
LIVE | Sep 18, 2026, 06:54 AM UTC
L
SNY - Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID
SNY - Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™
EQUITY | Sep 10, 2026, 01:06 PM UTC
L
RBC starts EU pharma coverage with Outperform ratings for AstraZeneca, Roche
RBC Capital Markets launched EU pharma coverage: Outperform for AstraZeneca and Roche, and Sector Perform for Sanofi, Novartis and GSK.
EQUITY | Sep 09, 2026, 02:43 PM UTC
L
SNY - Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
SNY - Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
EQUITY | Sep 08, 2026, 12:01 PM UTC
L
Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
MORRISTOWN, N.J., Sept. 8, 2026 // -- Sanofi is partnering with Emmy Award-winning actress, entrepreneur and mom Keke Palmer to help educate families about the importance of protection against serious RSV lung infection
EQUITY | Sep 08, 2026, 12:01 PM UTC
L
Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D
Sanofi SA (NASDAQ: SNY ) on Thursday reported second-quarter sales of $13.482 billion (11.597 billion euros), beating the consensus of $12.65 billion. Sales increased 16% year over year, up 17.8% in constant currency. Du
EARNINGS | Jul 30, 2026, 06:45 PM UTC
L
SNY Sanofi CEO notes "we have to catch up and benefit from the Wave of innovation that is emerging in China"
SNY Sanofi CEO notes "we have to catch up and benefit from the Wave of innovation that is emerging in China"
RATES | Jul 30, 2026, 11:50 AM UTC
M
Sanofi CEO Sees Moderate R&D Spend Increases
Sanofi plans moderate R&D spend increases
EQUITY | Jul 30, 2026, 11:44 AM UTC
L
SNY Sanofi RESULTS: Q2, Q2 free cash flow EUR 2.670B, Q2 REV EUR 11.597B vs. EST EUR 11.222B, Q2 Operating Income EUR 3.291B, Q2 Net Income
SNY Sanofi RESULTS: Q2, Q2 free cash flow EUR 2.670B, Q2 REV EUR 11.597B vs. EST EUR 11.222B, Q2 Operating Income EUR 3.291B, Q2 Net Income EUR 343M, Q2 EPS EUR 0.29
EARNINGS | Jul 30, 2026, 10:22 AM UTC
L
SNY Sanofi CEO belen garijo: we remain committed to immunology, rare diseases, and vaccines while we look for potentially additional growth
SNY Sanofi CEO belen garijo: we remain committed to immunology, rare diseases, and vaccines while we look for potentially additional growth opportunities - Media call Sanofi CEO notes will continue to complement our inte
RATES | Jul 30, 2026, 10:21 AM UTC
L
SNY announced that, as part of an ongoing R&D review, amlitelimab will be discontinued in Atopic Dermatitis despite positive results from th
SNY announced that, as part of an ongoing R&D review, amlitelimab will be discontinued in Atopic Dermatitis despite positive results from the ESTURY trial, as the data were not seen as sufficient to represent a meaningfu
EQUITY | Jul 24, 2026, 12:55 PM UTC
H
Trump Trade: U.S. to impose 100% tariff on imported generic drugs
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled. IMPORTED GENERIC DRUGS: U.S.
GEOPOLITICS | Jul 22, 2026, 02:08 PM UTC
H
Watch possibly MRK JNJ LLY PFE SNY AZN GSK NVS BMY RHHB after Trump post last night on generic drugs, and 100% tariff brought into US
Watch possibly MRK JNJ LLY PFE SNY AZN GSK NVS BMY RHHB after Trump post last night on generic drugs, and 100% tariff brought into US
GEOPOLITICS | Jul 22, 2026, 10:50 AM UTC
H
Trump to set 100% tariff on generic drugs brought into U.S. starting in 2028
U.S. President Donald...
GEOPOLITICS | Jul 21, 2026, 11:03 PM UTC
L
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for remainder of month: --ELVT expected around 7/23 – Drug rivoceranib + camrelizum
EQUITY | Jul 20, 2026, 05:31 PM UTC
H
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings
Prediction market platform Kalshi is expanding into biotech, launching contracts Wednesday night that let traders bet on clinical trial outcomes and drug approvals from companies including Sanofi (NASDAQ: SNY ) and Gilea
REGULATION | Jul 16, 2026, 05:29 PM UTC
L
Sanofi announces subcutaneous Sarclisa Escena approved in U.S.
The U.S. Food and Drug Administration has approved subcutaneous Sarclisa Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma across all existing indications of Sarclis
EQUITY | Jul 10, 2026, 12:43 PM UTC
L
WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over
WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over
EQUITY | Jul 02, 2026, 01:18 PM UTC
L
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints
On Tuesday, Sanofi SA (NASDAQ: SNY ) reported data from the Phase 3 Baby-COMET study of Nexviazyme (avalglucosidase alfa). Read Also: EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims P
EQUITY | Jun 30, 2026, 05:47 PM UTC
H
EU Probes Sanofi
The European Commission launches an antitrust investigation into Sanofi over allegedly misleading flu vaccine claims
REGULATION | Jun 26, 2026, 05:15 PM UTC
H
EU Probes Sanofi
The EU opens a formal antitrust investigation into Sanofi over the promotion of its flu vaccine
REGULATION | Jun 26, 2026, 09:48 AM UTC
H
Sanofi Wins EU Approval
Sanofi's multiple sclerosis drug Cenrifki approved in Europe despite FDA rejection
EQUITY | Jun 23, 2026, 04:42 PM UTC
M
SNY: Japan Approves Wayrilz
Sanofi's Wayrilz is approved in Japan for persistent or chronic immune thrombocytopenia based on the LUNA 3 Phase 3 study
EQUITY | Jun 23, 2026, 07:06 AM UTC
H
Sanofi Wins EU Approval
Sanofi secures EU approval for Cenrifki as first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
EQUITY | Jun 23, 2026, 07:01 AM UTC
M
Sanofi: Wayrilz Approved
Sanofi's Wayrilz is approved in Japan for immune thrombocytopenia based on the Luna 3 Phase 3 study
EQUITY | Jun 23, 2026, 05:17 AM UTC
M
Sanofi Gets EU Approval
Sanofi's Cenrifki is approved in the EU as the first disability-targeting treatment for non-relapsing secondary progressive multiple sclerosis
EQUITY | Jun 23, 2026, 05:05 AM UTC
M
MGNX Receives $24.5M Milestone
MacroGenics to receive $24.5M milestone from Sanofi following FDA approval of TZIELD expansion in type 1 diabetes
EARNINGS | Jun 22, 2026, 08:45 PM UTC